Your browser doesn't support javascript.
loading
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Dicanio, Marco; Giaccherini, Matteo; Clay-Gilmour, Alyssa; Macauda, Angelica; Sainz, Juan; Machiela, Mitchell J; Rybicka-Ramos, Malwina; Norman, Aaron D; Tyczynska, Agata; Chanock, Stephen J; Barington, Torben; Kumar, Shaji K; Bhatti, Parveen; Cozen, Wendy; Brown, Elizabeth E; Suska, Anna; Haastrup, Eva K; Orlowski, Robert Z; Dudzinski, Marek; Garcia-Sanz, Ramon; Kruszewski, Marcin; Martinez-Lopez, Joaquin; Beider, Katia; Iskierka-Jazdzewska, Elzbieta; Pelosini, Matteo; Berndt, Sonja I; Razny, Malgorzata; Jamroziak, Krzysztof; Rajkumar, S Vincent; Jurczyszyn, Artur; Vangsted, Annette Juul; Collado, Pilar Garrido; Vogel, Ulla; Hofmann, Jonathan N; Petrini, Mario; Butrym, Aleksandra; Slager, Susan L; Ziv, Elad; Subocz, Edyta; Giles, Graham G; Andersen, Niels Frost; Mazur, Grzegorz; Watek, Marzena; Lesueur, Fabienne; Hildebrandt, Michelle A T; Zawirska, Daria; Ebbesen, Lene Hyldahl; Marques, Herlander; Gemignani, Federica; Dumontet, Charles.
Afiliação
  • Dicanio M; Department of Biology, University of Pisa, Pisa, Italy.
  • Giaccherini M; Department of Biology, University of Pisa, Pisa, Italy.
  • Clay-Gilmour A; Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina, USA.
  • Macauda A; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sainz J; Genomic Oncology Area, GENYO. Center for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.
  • Machiela MJ; Department of Hematology, Virgen de las Nieves University Hospital, Granada, Spain.
  • Rybicka-Ramos M; Department of Medicine, University of Granada, Granada, Spain.
  • Norman AD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Tyczynska A; Department of Hematology Specialist Hospital No. 1, Bytom, Poland.
  • Chanock SJ; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Barington T; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Kumar SK; Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
  • Bhatti P; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Cozen W; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Brown EE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
  • Suska A; Cancer Control Research, BC Cancer, Vancouver, Canada.
  • Haastrup EK; Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Orlowski RZ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Dudzinski M; Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Garcia-Sanz R; Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Kruszewski M; Plasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
  • Martinez-Lopez J; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Beider K; Department of Lymphoma - Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Iskierka-Jazdzewska E; Department of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.
  • Pelosini M; Medina A. Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Berndt SI; Department of Hematology, University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland.
  • Razny M; Hospital 12 de Octubre, Compluntense University, CNIO, CIBERONC, Madrid, Spain.
  • Jamroziak K; Hematology Division Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Rajkumar SV; Department of Hematology, Medical University of Lodz, Lódz, Poland.
  • Jurczyszyn A; U.O. Dipartimento di Ematologia, Azienda USL Toscana Nord Ovest, Livorno, Italy.
  • Vangsted AJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Collado PG; Department of Hematology, Rydygier Hospital, Cracow, Poland.
  • Vogel U; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Hofmann JN; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Ontario, USA.
  • Petrini M; Plasma Cell Dyscrasia Center Department of Hematology Jagiellonian University Faculty of Medicine, Kraków, Poland.
  • Butrym A; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Slager SL; Department of Hematology, Virgen de las Nieves University Hospital, Granada, Spain.
  • Ziv E; National Research Center for the Working Environment, Copenhagen, Denmark.
  • Subocz E; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institues of Health, Bethesda, Maryland, USA.
  • Giles GG; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Andersen NF; Department of Cancer Prevention and Therapy, Wroclaw Medical University, Wroclaw, Poland.
  • Mazur G; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Ontario, USA.
  • Watek M; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
  • Lesueur F; Department of Hematology, Military Institute of Medicine, Warsaw, Poland.
  • Hildebrandt MAT; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Zawirska D; Center for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Ebbesen LH; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Marques H; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Gemignani F; Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
  • Dumontet C; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Int J Cancer ; 152(2): 239-248, 2023 01 15.
Article em En | MEDLINE | ID: mdl-36082445
ABSTRACT
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 × 10-8 ) with their respective trait. The selected SNPs were analyzed in 2434 MM cases and 3446 controls from the International Lymphoma Epidemiology Consortium (InterLymph). The 10 SNPs showing the strongest associations with MM risk in InterLymph were selected for replication in an independent set of 1955 MM cases and 1549 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and 418 MM cases and 147 282 controls from the FinnGen project. The combined analysis of the three studies identified an association between DNAJB4-rs34517439-A and an increased risk of developing MM (OR = 1.22, 95%CI 1.13-1.32, P = 4.81 × 10-7 ). rs34517439-A is associated with a modified expression of the FUBP1 gene, which encodes a multifunctional DNA and RNA-binding protein that it was observed to influence the regulation of various genes involved in cell cycle regulation, among which various oncogenes and oncosuppressors. In conclusion, with a pleiotropic scan approach we identified DNAJB4-rs34517439 as a potentially novel MM risk locus.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália